Amit Noheria1, Shiva P Ponamgi2, Christopher V Desimone1, Vaibhav R Vaidya3, Christopher A Aakre3, Elisa Ebrille4, Tiffany Hu5, David O Hodge6, Joshua P Slusser7, Naser M Ammash1, Charles J Bruce1, Alejandro A Rabinstein8, Paul A Friedman1, Samuel J Asirvatham9. 1. Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 2. Division of Hospital Internal Medicine, Mayo Clinic Health System, Austin, MN, USA. 3. Division of Internal Medicine, Mayo Clinic, Rochester, MN, USA. 4. Division of Cardiology, Città della Salute e della Scienza, University of Turin, Turin, Italy. 5. Mayo Medical School, Rochester, MN, USA. 6. Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA. 7. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 8. Department of Neurology, Mayo Clinic, Rochester, MN, USA. 9. Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA asirvatham.samuel@mayo.edu.
Abstract
BACKGROUND: Cardiac implantable electronic devices (CIEDs) are commonly associated with transvenous lead-related thrombi that can cause pulmonary embolism (PE). METHODS AND RESULTS: We retrospectively evaluated all patients with transvenous CIED leads implanted at Mayo Clinic Rochester between 1 January 2000, and 25 October 2010. Pulmonary embolism outcomes during follow-up were screened using diagnosis codes and confirmed with imaging study reports. Of 5646 CIED patients (age 67.3 ± 16.3 years, 64% men, mean follow-up 4.69 years) 88 developed PE (1.6%), incidence 3.32 [95% confidence interval (CI) 2.68-4.07] per 1000 person-years [men: 3.04 (95% CI 2.29-3.96) per 1000 person-years; women: 3.81 (95% CI 2.72-5.20) per 1000 person-years]. Other than transvenous CIED lead(s), 84% had another established risk factor for PE such as deep vein thrombosis (28%), recent surgery (27%), malignancy (25%), or prior history of venous thromboembolism (15%). At the time of PE, 22% had been hospitalized for ≥ 48 h, and 59% had been hospitalized in the preceding 30 days. Pulmonary embolism occurred in 22% despite being on systemic anticoagulation therapy. Out of 88 patients with PE, 45 subsequently died, mortality rate 93 (95% CI 67-123) per 1000 person-years (hazard ratio 2.0, 95% CI 1.5-2.7, P < 0.0001). CONCLUSIONS: Though lead-related thrombus is commonly seen in patients with transvenous CIED leads, clinical PE occurs with a low incidence. It is possible that embolism of lead thrombus is uncommon or emboli are too small to cause consequential pulmonary infarction. Published on behalf of the European Society of Cardiology. All rights reserved.
BACKGROUND: Cardiac implantable electronic devices (CIEDs) are commonly associated with transvenous lead-related thrombi that can cause pulmonary embolism (PE). METHODS AND RESULTS: We retrospectively evaluated all patients with transvenous CIED leads implanted at Mayo Clinic Rochester between 1 January 2000, and 25 October 2010. Pulmonary embolism outcomes during follow-up were screened using diagnosis codes and confirmed with imaging study reports. Of 5646 CIED patients (age 67.3 ± 16.3 years, 64% men, mean follow-up 4.69 years) 88 developed PE (1.6%), incidence 3.32 [95% confidence interval (CI) 2.68-4.07] per 1000 person-years [men: 3.04 (95% CI 2.29-3.96) per 1000 person-years; women: 3.81 (95% CI 2.72-5.20) per 1000 person-years]. Other than transvenous CIED lead(s), 84% had another established risk factor for PE such as deep vein thrombosis (28%), recent surgery (27%), malignancy (25%), or prior history of venous thromboembolism (15%). At the time of PE, 22% had been hospitalized for ≥ 48 h, and 59% had been hospitalized in the preceding 30 days. Pulmonary embolism occurred in 22% despite being on systemic anticoagulation therapy. Out of 88 patients with PE, 45 subsequently died, mortality rate 93 (95% CI 67-123) per 1000 person-years (hazard ratio 2.0, 95% CI 1.5-2.7, P < 0.0001). CONCLUSIONS: Though lead-related thrombus is commonly seen in patients with transvenous CIED leads, clinical PE occurs with a low incidence. It is possible that embolism of lead thrombus is uncommon or emboli are too small to cause consequential pulmonary infarction. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: C Ozcan; A Jahangir; P A Friedman; P J Patel; T M Munger; R F Rea; M A Lloyd; D L Packer; D O Hodge; B J Gersh; S C Hammill; W K Shen Journal: N Engl J Med Date: 2001-04-05 Impact factor: 91.245
Authors: Vaibhav R Vaidya; Christopher V DeSimone; Samuel J Asirvatham; Vishnu M Chandra; Amit Noheria; David O Hodge; Joshua P Slusser; Alejandro A Rabinstein; Paul A Friedman Journal: J Interv Card Electrophysiol Date: 2014-04-27 Impact factor: 1.900
Authors: Charles J Lenz; Christopher V DeSimone; Shiva P Ponamgi; Alan Sugrue; Lawrence J Sinak; Krishnaswamy Chandrasekaran; Douglas L Packer; Samuel J Asirvatham Journal: J Interv Card Electrophysiol Date: 2016-02-22 Impact factor: 1.900
Authors: Shiva P Ponamgi; Vaibhav R Vaidya; Christopher V Desimone; Amit Noheria; David O Hodge; Joshua P Slusser; Naser M Ammash; Charles J Bruce; Alejandro A Rabinstein; Paul A Friedman; Samuel J Asirvatham Journal: Pacing Clin Electrophysiol Date: 2017-02-07 Impact factor: 1.976
Authors: Alan Sugrue; Christopher V DeSimone; Charles J Lenz; Douglas L Packer; Samuel J Asirvatham Journal: J Interv Card Electrophysiol Date: 2015-12-09 Impact factor: 1.900
Authors: Caio Marcos de Moraes Albertini; Katia Regina da Silva; Joaquim Maurício da Motta Leal Filho; Elizabeth Sartori Crevelari; Martino Martinelli Filho; Francisco Cesar Carnevale; Roberto Costa Journal: Arq Bras Cardiol Date: 2018-09-21 Impact factor: 2.000